The stock of Nurix Therapeutics Inc (NRIX) has gone down by -4.87% for the week, with a -11.98% drop in the past month and a 65.57% rise in the past quarter. The volatility ratio for the week is 7.05%, and the volatility levels for the past 30 days are 8.78% for NRIX. The simple moving average for the past 20 days is -8.61% for NRIX’s stock, with a 38.46% simple moving average for the past 200 days.
Is It Worth Investing in Nurix Therapeutics Inc (NASDAQ: NRIX) Right Now?
The stock has a 36-month beta value of 2.10. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NRIX is 54.63M, and at present, short sellers hold a 12.88% of that float. On May 02, 2024, the average trading volume of NRIX was 1.03M shares.
NRIX) stock’s latest price update
The stock price of Nurix Therapeutics Inc (NASDAQ: NRIX) has surged by 8.82 when compared to previous closing price of 12.02, but the company has seen a -4.87% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-10 that Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with Oppenheimer repeating the rating for NRIX by listing it as a “Outperform.” The predicted price for NRIX in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 26, 2023 of the previous year 2023.
Barclays, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $20. The rating they have provided for NRIX stocks is “Overweight” according to the report published on March 09th, 2023.
Oppenheimer gave a rating of “Outperform” to NRIX, setting the target price at $25 in the report published on February 28th of the previous year.
NRIX Trading at -3.88% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.81% of loss for the given period.
Volatility was left at 8.78%, however, over the last 30 days, the volatility rate increased by 7.05%, as shares sank -10.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.63% upper at present.
During the last 5 trading sessions, NRIX fell by -4.87%, which changed the moving average for the period of 200-days by +32.66% in comparison to the 20-day moving average, which settled at $14.24. In addition, Nurix Therapeutics Inc saw 26.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from Hansen Gwenn, who sale 2,007 shares at the price of $12.04 back on Apr 30 ’24. After this action, Hansen Gwenn now owns 39,601 shares of Nurix Therapeutics Inc, valued at $24,169 using the latest closing price.
Ring Christine, the Chief Legal Officer of Nurix Therapeutics Inc, sale 1,513 shares at $12.04 during a trade that took place back on Apr 30 ’24, which means that Ring Christine is holding 19,838 shares at $18,220 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -1.95 for the present operating margin
- 0.82 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -1.76. The total capital return value is set at -0.7. Equity return is now at value -65.37, with -42.39 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.74. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -29.14.
Currently, EBITDA for the company is -141.41 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 9.34. The receivables turnover for the company is 101.11for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.86.
Conclusion
To sum up, Nurix Therapeutics Inc (NRIX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
